Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020068058 - ANTI-SIGLEC ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USES THEREOF

Publication Number WO/2020/068058
Publication Date 02.04.2020
International Application No. PCT/US2018/052759
International Filing Date 25.09.2018
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/08 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
C12P 21/08 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21Preparation of peptides or proteins
08Monoclonal antibodies
G01N 33/576 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
576for hepatitis
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/2803
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
C07K 2317/77
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
77Internalization into the cell
G01N 33/576
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
576for hepatitis
Applicants
  • ACADEMIA SINICA
  • YANG, An-Suei [US]/[US]
Inventors
  • YANG, An-Suei
  • HSIEH, Shie-Liang
  • TSAI, Tsung-Yu
  • YU, Chung-Ming
  • PENG, Cheng-Yuan
Agents
  • HUANG, Angela
Priority Data
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-SIGLEC ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USES THEREOF
(FR) ANTICORPS ANTI-SIGLEC, COMPOSITION PHARMACEUTIQUE LE COMPRENANT, ET LEURS UTILISATIONS
Abstract
(EN)
Disclosed herein is a novel monoclonal antibody exhibiting binding affinity to Siglec-3 receptor. According to the embodiment, the monoclonal antibody is capable of reversing HBV-induced immunosuppression. Accordingly, also disclosed herein are the uses thereof in the treatment and/or prophylaxis of hepatitis B virus (HBV) infection.
(FR)
La présente invention concerne un nouvel anticorps monoclonal présentant une affinité de liaison pour le récepteur Siglec-3. Selon le mode de réalisation, l'anticorps monoclonal est capable d'inverser l'immunosuppression induite par le VHB. Par conséquent, la présente invention concerne également ses utilisations dans le traitement et/ou la prophylaxie d'une infection par le virus de l'hépatite B (VHB).
Latest bibliographic data on file with the International Bureau